🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Oncopeptides AB (publ) (STO:ONCO)
Sweden flag Sweden · Delayed Price · Currency is SEK
1.640
-0.051 (-3.02%)
Nov 20, 2026, 5:29 PM CET

Oncopeptides AB Statistics

Total Valuation

Oncopeptides AB has a market cap or net worth of SEK 648.27 million. The enterprise value is 671.85 million.

Market Cap648.27M
Enterprise Value 671.85M

Important Dates

The last earnings date was Thursday, November 5, 2026.

Earnings Date Nov 5, 2026
Ex-Dividend Date n/a

Share Statistics

Oncopeptides AB has 395.29 million shares outstanding. The number of shares has increased by 49.53% in one year.

Current Share Class 381.36M
Shares Outstanding 395.29M
Shares Change (YoY) +49.53%
Shares Change (QoQ) -6.24%
Owned by Insiders (%) 0.50%
Owned by Institutions (%) 9.39%
Float 379.39M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 6.26
PB Ratio n/a
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 6.49
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.75

Current Ratio 3.75
Quick Ratio 3.45
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -199.12

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -101.27%
Return on Invested Capital (ROIC) -82.90%
Return on Capital Employed (ROCE) -140.34%
Weighted Average Cost of Capital (WACC) 1.33%
Revenue Per Employee 1.46M
Profits Per Employee -2.76M
Employee Count71
Asset Turnover 0.53
Inventory Turnover 0.33

Taxes

In the past 12 months, Oncopeptides AB has paid 1.85 million in taxes.

Income Tax 1.85M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -67.97% in the last 52 weeks. The beta is -0.50, so Oncopeptides AB's price volatility has been lower than the market average.

Beta (5Y) -0.50
52-Week Price Change -67.97%
50-Day Moving Average 1.92
200-Day Moving Average 1.73
Relative Strength Index (RSI) 40.16
Average Volume (20 Days) 3,176,673

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Oncopeptides AB had revenue of SEK 103.50 million and -196.04 million in losses. Loss per share was -0.61.

Revenue103.50M
Gross Profit 99.90M
Operating Income -185.19M
Pretax Income -194.20M
Net Income -196.04M
EBITDA -183.05M
EBIT -185.19M
Loss Per Share -0.61
Full Income Statement

Balance Sheet

The company has 116.84 million in cash and 140.42 million in debt, with a net cash position of -23.58 million or -0.06 per share.

Cash & Cash Equivalents 116.84M
Total Debt 140.42M
Net Cash -23.58M
Net Cash Per Share -0.06
Equity (Book Value) -16.50M
Book Value Per Share -0.04
Working Capital 120.78M
Full Balance Sheet

Cash Flow

Operating Cash Flow -192.57M
Capital Expenditures n/a
Depreciation & Amortization 2.13M
Net Borrowing -8.16M
Free Cash Flow -192.57M
FCF Per Share -0.49
Full Cash Flow Statement

Margins

Gross margin is 96.52%, with operating and profit margins of -178.92% and -189.41%.

Gross Margin 96.52%
Operating Margin -178.92%
Pretax Margin -187.63%
Profit Margin -189.41%
EBITDA Margin -176.86%
EBIT Margin -178.92%
FCF Margin n/a

Dividends & Yields

Oncopeptides AB does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -49.53%
Shareholder Yield -49.53%
Earnings Yield -37.06%
FCF Yield -29.71%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Analyst Forecast

The average price target for Oncopeptides AB is 2.70, which is 64.63% higher than the current price. The consensus rating is "Hold".

Price Target 2.70
Price Target Difference 64.63%
Analyst Consensus Hold
Analyst Count 2
Revenue Growth Forecast (3Y) 66.45%
EPS Growth Forecast (3Y) n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 3